Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Stents for small airways: current practice..
Expert Rev Respir Med. 14(10), 969-972.
(2020). A 3D Polymer Model for Future Nutrition Design Novel Nutrition Approach for Cystic Fibrosis, Ulcerative Colitis and Crohn's Disease..
J Nanomedine Biotherapeutic Discov. 4(2), 128.
(2014). Treatment of non-small cell lung cancer (NSCLC)..
J Thorac Dis. 5 Suppl 4, S389-96.
(2013). Management of malignant pleural effusion by suicide gene therapy in advanced stage lung cancer: a case series and literature review..
Cancer Gene Ther. 19(9), 593-600.
(2012). Immunotherapy "Shock" with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma..
Respir Med Case Rep. 22, 283-286.
(2017). New insights for IL-6 targeted therapy as an adjuvant treatment for non-small-cell lung cancer..
Ther Deliv. 4(10), 1221-3.
(2013). Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases..
Respir Med Case Rep. 22, 101-105.
(2017). The role of second-line chemotherapy in small cell lung cancer: a retrospective analysis..
Onco Targets Ther. 6, 1493-500.
(2013). Establishing the optimal nebulization system for paclitaxel, docetaxel, cisplatin, carboplatin and gemcitabine: back to drawing the residual cup..
Int J Pharm. 453(2), 480-7.
(2013). Vapor for lung volume reduction; pros and cons..
Expert Rev Respir Med. 14(12), 1189-1195.
(2020). Elastography during convex-probe (endobronchial ultrasound) for optimal biopsy sample and gene identification in non-small-cell lung cancer..
Biomark Med. 13(14), 1153-1156.
(2019). Orbital metastases as the first manifestation of lung adenocarcinoma..
Case Rep Ophthalmol. 2(1), 34-8.
(2011). A chrono-target chemotherapy treatment model for lung cancer treatment..
Ther Deliv. 4(1), 5-8.
(2013). Further experimentation of inhaled; LANTUS, ACTRAPID and HUMULIN with todays' production systems..
Int J Pharm. 458(1), 39-47.
(2013). Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 ≥50..
Transl Lung Cancer Res. 7(Suppl 1), S28-S30.
(2018). Long-term respiratory follow-up of H1N1 infection..
Virol J. 8, 319.
(2011). New insights in the production of aerosol antibiotics. Evaluation of the optimal aerosol production system for ampicillin-sulbactam, meropenem, ceftazidime, cefepime and piperacillin-tazobactam..
Int J Pharm. 455(1-2), 182-8.
(2013). Experimentation with inhaled bronchodilators and corticosteroids..
Int J Pharm. 461(1-2), 411-8.
(2014). Interleukin-8 and interleukin-17 for cancer..
Cancer Invest. 32(5), 197-205.
(2014). Inhaled cisplatin deposition and distribution in lymph nodes in stage II lung cancer patients..
Future Oncol. 9(9), 1307-13.
(2013). Connection between PD-L1 expression and standardized uptake value in NSCLC: an early prognostic treatment combination..
Expert Rev Respir Med.
(2020). Malignant pleural effusion and algorithm management..
J Thorac Dis. 5 Suppl 4, S413-9.
(2013). A 26-year-old male with mesothelioma due to asbestos exposure..
Case Rep Med. 2011, 951732.
(2011). Clinical experimentation with aerosol antibiotics: current and future methods of administration..
Drug Des Devel Ther. 7, 1115-34.
(2013).
(2012).